Mometasone Furoate/Olopatadine Glenmark (Mometasone Furoate, Olopatadine)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, leading to reduced production of inflammatory cytokines and decreased infiltration of inflammatory cells. This anti‑inflammatory action helps to shrink swollen nasal tissue and lower mucus production.

The specific dosing regimen for Mometasone Furoate/Olopatadine is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and overall health status. Patients should follow the prescriber’s instructions and the product label.

Safety data for use during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing this medication to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent antihistamine sprays, the Mometasone Furoate/Olopatadine combo offers both anti‑inflammatory and antihistaminic effects, potentially providing more comprehensive symptom control. Unlike oral antihistamines, the nasal route delivers medication directly to the site of inflammation, reducing systemic exposure.

Store the nasal spray at ambient temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

The product is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, severe allergic reactions such as anaphylaxis, nasal septum perforation, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience symptoms like severe nosebleeds, vision changes, or signs of systemic infection.

Individuals with known hypersensitivity to mometasone furoate, olopatadine, or any component of the formulation should avoid this product. It is also contraindicated in patients with active untreated nasal infections or recent nasal surgery unless specifically advised by a healthcare professional.